Your session is about to expire
← Back to Search
Virus Vaccine
Yellow Fever Vaccine 17D Immunogenicity for Yellow Fever
Phase 1 & 2
Recruiting
Led By William Messer, MD PhD
Research Sponsored by Oregon Health and Science University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
No Placebo-Only Group
Summary
This trial studies how prior vaccination affects the immune response to the yellow fever vaccine 17D in adults. Participants will provide medical and travel histories, blood samples, and a daily diary of symptoms.
Who is the study for?
Adults aged 20-49 who are in good health and have been previously vaccinated with the yellow fever vaccine (17D) at least 8 years ago. They must be able to follow trial procedures, provide a detailed medical history, and not plan to travel to yellow fever endemic areas during the trial.
What is being tested?
The study is testing how well adults respond to a re-vaccination of the yellow fever vaccine (17D). It looks at antibody responses and immune cell reactions after getting another dose of the same vaccine they received before.
What are the potential side effects?
Participants may experience symptoms similar to those from their initial vaccination, which can include mild fever, soreness at injection site, or fatigue. A daily diary will help track any side effects for two weeks post-vaccination.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Neutralizing antibody titer boost following vaccination
vaccine viremia following vaccination
Secondary study objectives
CD4+ immune cell response to vaccination
Other study objectives
CD8+ immune cell response to vaccination
Memory B cell response to vaccination
cytokine response to vaccination
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Vaccination armExperimental Treatment1 Intervention
Participants will receive a standard dose of of the yellow fever vaccine 17D (YFVax(r)), 0.5mL suspension in normal saline administered subcutaneously once.
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Oregon Health and Science UniversityLead Sponsor
1,008 Previous Clinical Trials
7,414,274 Total Patients Enrolled
William Messer, MD PhDPrincipal InvestigatorOregon Health and Science University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am able to have children, sexually active, and haven't used birth control for 2 months.I am either male or female.I have a history of neurological disorders or seizures.I am between 20 and 49 years old.I have an original record of a Yellow fever vaccination given over 8 years ago.I am in good health according to my doctor's assessment.I haven't had a fever or active infection in the last 3 days.
Research Study Groups:
This trial has the following groups:- Group 1: Vaccination arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.